<DOC>
	<DOCNO>NCT02190123</DOCNO>
	<brief_summary>REWINDER multinational , multicentre , non-interventional , retrospective study patient treat oral antiplatelet ( ticagrelor , prasugrel clopidogrel ) hospital acute coronary syndrome ( ACS ) event , conduct Belgium Luxembourg . Primary objective evaluate actual treatment persistence oral antiplatelets ( OAP ) ACS clinical practice Belgium Luxembourg . The main secondary objective describe frequent reason OAP treatment switch , discontinuation reinitiation ; identify decisionmakers OAP treatment change characterize patient profile term demographic , diagnosis , management strategy , comorbidities concomitant medication identify association patient profile treatment duration .</brief_summary>
	<brief_title>REalWorld Insights INitiation Treatment Duration ticagrEloR &amp; Other Oral Antiplatelets ( OAP ) Patients With Acute Coronary Syndrome ( ACS ) Be/Lux .</brief_title>
	<detailed_description>Treatment acute coronary syndrome ( ACS ) oral antiplatelets ( OAPs ) recommend 12 month unless discontinuation clinically indicate . Early discontinuation could result increase risk cardiovascular death myocardial infarction due patient 's underlying disease . There robust data allow evaluate treatment persistence OAPs ACS current practice Belgium Luxembourg time . It currently unclear patient discontinue , switch reinitiate treatment upon whose advice . A non-interventional study need obtain reliable data treatment persistence reason discontinuation , switch reinitiation treatment . REWINDER multinational , multicentre , non-interventional , retrospective study patient treat oral antiplatelet ( ticagrelor , prasugrel clopidogrel ) hospital ACS event , conduct Belgium Luxembourg . Primary objective evaluate actual treatment persistence OAPs ACS clinical practice Belgium Luxembourg . The main secondary objective describe frequent reason OAP treatment switch , discontinuation reinitiation ; identify decisionmakers OAP treatment change characterize patient profile term demographic , diagnosis , management strategy , comorbidities concomitant medication identify association patient profile treatment duration . The target sample size study 500 patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>The patient population observe NIS must fulfil follow criterion : 1 . Female male age â‰¥18 year 2 . A patient information letter send Investigator patient 3 . Patient discharge alive hospital home follow ACS ( diagnose STEMI , NSTEMI UA ) 4 . ACS either UA myocardial infarction Type 1 ( spontaneous myocardial infarction relate ischemia due primary coronary event plaque erosion and/or rupture , fissuring , dissection ) 5 . ACS 1st July 2012 1st June 2013 6 . Patient ticagrelor , prasugrel clopidogrel treatment discharge follow ACS Patients eligible participate follow exclusion criterion present : 1 . Patient participate interventional clinical study observation period . 2 . Patient ACS precipitate complication surgery , trauma , gastrointestinal bleeding Percutaneous Coronary Intervention ( PCI ) 3 . Patient ACS occur stay hospital</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Acute Coronary Syndrome ( ACS )</keyword>
	<keyword>Oral antiplatelets ( ticagrelor , prasugrel , clopidogrel ) ( OAP )</keyword>
	<keyword>Treatment persistence .</keyword>
</DOC>